Results 61 to 70 of about 1,365 (131)

[Academic impact of COVID-19 on students at a Peruvian university]. [PDF]

Aten Primaria
Valenzuela Muñoz A, Meza Aguirre MR, Valenzuela Ramos MR, Dias Monteiro PM.   +3 more
europepmc   +1 more source

Epidemiological outlook for vector-borne diseases: Learned lessons and challenges to break the circle [PDF]

Biomedica, 2023
Padilla-Rodríguez JC.
europepmc   +1 more source

Out-of-pocket expenditures on child health during an economic recession in Brazil. [PDF]

Rev Saude Publica
Silva MTD, Tejada CAO, Aristides AM, Matijasevich A, Santos IS, Bertoldi AD.   +5 more
europepmc   +1 more source

Proof-of-Concept Study on the Use of Tangerine-Derived Nanovesicles as siRNA Delivery Vehicles toward Colorectal Cancer Cell Line SW480. [PDF]

Int J Mol Sci, 2023
Rabienezhad Ganji N, Urzì O, Tinnirello V, Costanzo E, Polito G, Palumbo Piccionello A, Manno M, Raccosta S, Gallo A, Lo Pinto M, Calligaris M, Scilabra SD, Di Bella MA, Conigliaro A, Fontana S, Raimondo S, Alessandro R.   +16 more
europepmc   +1 more source

Burden clinico ed economico delle infezioni del tratto urinario nei pazienti con lesioni midollari e sclerosi multipla in Italia. [PDF]

Glob Reg Health Technol Assess
Rumi F, Fortunato A, Di Brino E, Basile M, Antonini D, De Palma L, Del Popolo G, Collaborators (in alphabetical order) .   +7 more
europepmc   +1 more source

ELECCIONES Y CICLOS ECONÓMICOS EN MÉXICO

El Trimestre Económico, 2007
Daniel Flores Curiel
doaj  

Challenges for the elimination of neglected tropical disease in Latin America and the Caribbean [PDF]

Biomedica
Nicholls RS.
europepmc   +1 more source

The Hidden Cost of Denied Access: Advanced Heart Failure in Latin America. [PDF]

Arq Bras Cardiol
Andrade FA.
europepmc   +1 more source

Multicriterio e valutazioni economiche: verso una proposta per un nuovo framework per il prezzo dei farmaci in Italia. [PDF]

Glob Reg Health Technol Assess
Marcellusi A, Maggioni AP, Mandorino AL, Caprari F, Marzona I, Jommi C.   +5 more
europepmc   +1 more source

Analisi di costo-efficacia di nirmatrelvir/ritonavir in pazienti adulti ad alto rischio di progressione a COVID-19 severo. [PDF]

Glob Reg Health Technol Assess
Moreno C, Aiello A, Di Virgilio R, Mazzotta V, Antinori A.   +4 more
europepmc   +1 more source